Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma
A legfontosabb adatok
- Hol
- Dallas, Jacksonville, Rochester és Scottsdale (Egyesült Államok)Mind a 5 helyszín megnézése
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 90 év között vagy?
Forrás: NCT07212491: ki vehet részt
Helyszínek itt: Egyesült Államok
- Baylor Scott & White Research InstituteDallas, Egyesült ÁllamokNo longer taking part
- Mayo Clinic in FloridaJacksonville, Egyesült ÁllamokNo longer taking part
- Mayo Clinic in RochesterRochester, Egyesült ÁllamokNo longer taking part
- University of Rochester Medical CenterRochester, Egyesült ÁllamokNo longer taking part
- Mayo Clinic in ArizonaScottsdale, Egyesült ÁllamokNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Mayo Clinic
- Azonosító
- NCT07212491
- A regiszteradat frissítve
- 2026. szeptember 29.
- Eredeti leírás
This study explores the use of a minimally invasive screening tool (a sponge on a string device) to detect Barrett's esophagus and esophageal adenocarcinoma and to develop a laboratory test for the detection of Barrett's esophagus-high grade dysplasia and esophageal adenocarcinoma.A teljes eredeti leírásKevesebb
Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma- Renewal Grant Aim 2 (The SOS6C Trial)
This study explores the use of a minimally invasive screening tool (a sponge on a string device) to detect Barrett's esophagus and esophageal adenocarcinoma and to develop a laboratory test for the detection of Barrett's esophagus-high grade dysplasia and esophageal adenocarcinoma.
Bevonási feltételek: Patient between the ages 18 - 90; Patients with a BE segment >= 1cm in maximal extent endoscopically; Histology showing evidence of intestinal metaplasia with or without presence of dysplasia; Undergoing clinically indicated endoscopy.
Kizáró feltételek: Patients with a prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with a history of endoscopic mucosal resection alone will not be excluded; Subjects with known evidence of BE (on history or review of medical records); Pregnant or lactating females; Patients who are unable to consent; Patients with a current history of uninvestigated dysphagia [does not apply to the brushings/biopsies only portion of the study for Mayo Clinic in Rochester (RST)/Mayo Clinic in Arizona (ARZ) sites only]; History of eosinophilic esophagitis or achalasia; Patients on oral anticoagulation including Coumadin, and warfarin, unless discontinued for thee to five days prior to the sponge procedure. (This does not apply to the brushing/biopsy only portion of the study for RST/ARZ sites only); Patients on antiplatelet agents including clopidogrel, unless discontinued for three to five days prior to the sponge procedure. (This does not apply to the brushing/biopsy only portion of the study for RST/ARZ sites only); Patients on oral thrombin inhibitors including dabigatran and oral factor X an inhibitor such as rivaroxaban, apixaban, and edoxaban, unless discontinued for three to five days prior to the sponge procedure. (This does not apply to the brushing/biopsy only portion of the study for RST/ARZ sites only); Patients with a history of known esophageal or gastric varices or cirrhosis; Patients with a history of esophageal or gastric resection; Patients with congenital or acquired bleeding diatheses; Patients with a history of esophageal squamous dysplasia; Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment; Patient has received chemotherapy class drugs or radiation to treat mediastinal or esophageal cancer; Patients with Familial Adenomatous Polyposis (FAP) or Lynch Syndrome; Patients with a history of esophageal or gastric resection for esophageal or gastric carcinoma.